Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
McKernan; Patricia A.
Address:
Woodinville, WA
No. of patents:
13
Patents:












Patent Number Title Of Patent Date Issued
7101907 Topical administration of statins for treatment of bone disorders September 5, 2006
The topical administration of statins for the treatment of bone disorders is disclosed.
6642216 Isoprenoid pathway inhibitors for stimulating bone growth November 4, 2003
Compounds of the formula ##STR1##wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula ##STR2## or a stereoisomer thereof, wherein R.sup.1 is substituted or unsubstituted alkyl
6395740 Calcitonin mimetics May 28, 2002
Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre
6391917 Dialkyl ureas as calcitonin mimetics May 21, 2002
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6376476 Isoprenoid pathway inhibitors for stimulating bone growth April 23, 2002
Various embodiments of statin compounds are shown to enhance the formation of bone and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-pl
6255351 Dialkyl ureas as calcitonin mimetics July 3, 2001
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6221913 Dialkyl ureas as calcitonin mimetics April 24, 2001
Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin rec
6124299 Calcitonin mimetics September 26, 2000
Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the pre
6080779 Compositions and methods for stimulating bone growth June 27, 2000
Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may opti
6022887 Compositions and methods for stimulating bone growth February 8, 2000
Compounds of the formula ##STR1## wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C;Y represents one or more carbocyclic or heterocyclic rings; when two or more rings are present in Y, they may optio
5698521 Native calcitonin mimetics December 16, 1997
The invention provides isolated, biologically active native calcitonin mimetics and related methods. These small 16 and 17 amino acid proteins mimic the interaction of calcitonin on its receptor, and also exhibit bone resorptive inhibiting activity.
5677334 Method for inhibiting the stimulation of a glucagon-induced response pathway in a warm-blooded a October 14, 1997
Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response
5508304 Glucagon antagonists and methods relating thereto April 16, 1996
Glucagon antagonists and methods relating thereto are disclosed. The glucagon antagonists include skyrin and skyrin analogs, and serve to inhibit the stimulation of a glucagon-induced response pathway, such as the adenylate cyclase response pathway or the inositol phosphate response










 
 
  Recently Added Patents
Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
Distributed multicast packet replication with centralized quality of service
Multilayer films having reduced curling
Spacers for insulated glass units
Method and computed tomography device and data storage medium for performing a dynamic CT examination on a patient
Asynchronous distributed de-duplication for replicated content addressable storage clusters
Vehicle display system or projection display for a motor vehicle, and calibration method
  Randomly Featured Patents
Method for efficiently revoking digital identities
Intelligent battery system
Managing users in a multi-user network game environment
Method and electronic regulator with a current measuring circuit for measuring the current by sense-FET and sigma-delta modulation
Drive assembly for a power tool
Coating system utilizing an oxide diffusion barrier for improved performance and repair capability
Diagnostic reagents for renal function disorders and method for analyzing urine samples
Apparatus for driving power seat for vehicle
Object identification system
Transmission device control system equipped with high-efficiency coding scheme in communication network